Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00113919 · MORE INFO

Limitations, agreements, and source contact

UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients · Source last updated 2017-10-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
Early termination, only 5 of the 14 completed, reasons as follows: Death Unrelated to Protocol Adverse Event Relapse Patient Choice
point Of Contact
email
pettynathanm@uams.edu
organization
University of Arkansas for Medical Sciences
phone
501-837-3894
title
Nathan Petty
Complete source fields
certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
Early termination, only 5 of the 14 completed, reasons as follows: Death Unrelated to Protocol Adverse Event Relapse Patient Choice
point Of Contact
email
pettynathanm@uams.edu
organization
University of Arkansas for Medical Sciences
phone
501-837-3894
title
Nathan Petty

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice